gevokizumab + bevacizumab + FOLFIRI

This drug is a **combination regimen** composed of three components: - **Gevokizumab** is a monoclonal antibody targeting interleukin-1 beta (IL-1β), primarily developed as an anti-inflammatory and immunomodulatory agent. It has been investigated primarily in inflammatory diseases but may be included in oncology regimens for its immunomodulatory potential. - **Bevacizumab** is a monoclonal antibody that binds to vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis, which is essential for tumor growth and metastasis. - **FOLFIRI** is a chemotherapy regimen consisting of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. Leucovorin enhances 5-FU activity; 5-FU is an antimetabolite inhibiting thymidylate synthase and incorporating into RNA and DNA to disrupt synthesis; irinotecan is a topoisomerase I inhibitor that causes lethal DNA damage in proliferating cancer cells[1][3][5]. Together, this combination is most likely designed for the treatment of advanced/metastatic colorectal cancer, using cytotoxic chemotherapy (FOLFIRI), anti-angiogenic therapy (bevacizumab), and immunomodulation (gevokizumab).